尼拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的最终总生存分析
MAGNITUDE 3期试验纳入HRR基因改变的mCRPC患者,随机接受尼拉帕利+阿比特龙+泼尼松(AAP)或安慰剂+AAP。最终分析中位随访37.3个月,HRR+人群总生存无显著差异(HR 0.931,95%CI 0.720-1.203;p=0.585),但症状进展时间和至化疗时间显著改善。
要点
- HRR+ mCRPC患者中尼拉帕利+AAP未显著改善总生存。
- BRCA1/2亚组总生存也无显著差异(HR 0.788,95%CI 0.554-1.120)。
- 尼拉帕利+AAP显著延长至症状进展时间和至化疗时间。
核心结论
- HRR+ mCRPC患者,包括BRCA突变者,一线尼拉帕利+AAP对比安慰剂+AAP总体仍可获益。
研究设计与样本
- 3期MAGNITUDE试验,前瞻性筛选HRR改变,1:1随机至尼拉帕利+AAP(n=212)或安慰剂+AAP(n=211)。
- 报告预设的事件驱动最终分析,中位随访37.3个月。
主要发现
- HRR+人群总生存无差异(HR 0.931,95%CI 0.720-1.203;p=0.585)。
- BRCA1/2亚组总生存无显著差异(HR 0.788,95%CI 0.554-1.120;名义p=0.183)。
- 多因素调整后HRR+人群总生存有延长趋势(HR 0.785,95%CI 0.606-1.016;名义p=0.066),BRCA1/2亚组(HR 0.663,95%CI 0.464-0.947;名义p=0.024)。
- 至症状进展时间在HRR+人群(HR 0.547,95%CI 0.396-0.754;p=0.006)和BRCA1/2亚组(HR 0.562,95%CI 0.371-0.849;名义p=0.006)均显著改善。
- 至细胞毒化疗时间在HRR+人群(HR 0.688,95%CI 0.499-0.950;p=0.022)和BRCA1/2亚组(HR 0.598,95%CI 0.387-0.924;名义p=0.019)均有临床意义改善。
临床怎么用
- 对于HRR+ mCRPC,尤其是BRCA突变者,一线尼拉帕利+AAP可作为治疗选择,尽管总生存未显著改善,但延迟症状进展和化疗需求。
局限性
- 总生存分析未达统计学显著差异,多因素分析结果仅为趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The phase 3 MAGNITUDE trial previously met its primary endpoint of an improvement in radiographic progression-free survival with niraparib + abiraterone acetate and prednisone (AAP) versus placebo + AAP in patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in genes involved in DNA homologous recombination repair (HRR+), particularly in BRCA1/2. METHODS: Patients were prospectively screened for HRR alterations and randomized 1:1 to niraparib + AAP (n = 212) or placebo + AAP (n = 211). We report results from the prespecified, event-driven, final analysis of secondary efficacy endpoints. KEY FINDINGS AND LIMITATIONS: Final analysis at median follow-up of 37.3 mo revealed no difference in overall survival (OS) between niraparib + AAP and placebo + AAP in the HRR+ population (hazard ratio [HR] 0.931, 95% confidence interval [CI] 0.720-1.203; p = 0.585) or the subgroup with BRCA1/2 alterations (HR 0.788, 95% CI 0.554-1.120; nominal p = 0.183). Prespecified multivariate analyses adjusted for baseline prognostic factors showed a trend toward longer OS with niraparib + AAP over placebo + AAP in the HRR+ population (HR 0.785, 95% CI 0.606-1.016; nominal p = 0.066) and the BRCA1/2 subgroup (HR 0.663, 95% CI 0.464-0.947; nominal p = 0.024). Niraparib + AAP led to a statistically significant, clinically meaningful improvement in time to symptomatic progression in both the HRR+ population (HR 0.547, 95% CI 0.396-0.754; p = 0.006) and the BRCA1/2 subgroup (HR 0.562, 95% CI 0.371-0.849; nominal p = 0.006), and a clinically meaningful improvement in time to cytotoxic chemotherapy in the HRR+ population (HR 0.688, 95% CI 0.499-0.950; p = 0.022) and the BRCA1/2 subgroup (HR 0.598, 95% CI 0.387-0.924; nominal p = 0.019) in comparison to placebo + AAP. The niraparib + AAP safety profile remains unchanged at longer follow-up; adverse events were primarily hematologic and manageable. CONCLUSIONS AND CLINICAL IMPLICATIONS: The MAGNITUDE final analysis showed that patients with HRR+ mCRPC, including those with the approved indication of BRCA-altered mCRPC, generally continue to benefit from first-line treatment with niraparib + AAP in comparison to placebo + AAP.
引用
- Chi KN, Castro E, Attard G, et al. Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. Eur Urol Oncol. 2025. PMID: 40328571. doi:10.1016/j.euo.2025.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。